New triple therapy aims to control hard-to-treat head and neck cancer
NCT ID NCT06308913
First seen Apr 23, 2026 · Last updated May 13, 2026 · Updated 4 times
Summary
This early-stage study tests a new drug (INCB081776) combined with standard immunotherapy (pembrolizumab) and palliative radiation in 10 people whose head and neck cancer has returned or spread. The main goal is to check safety and side effects. Researchers will also see if the treatment helps shrink tumors or control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UW Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.